Source-first knowledge base

Daraxon research library

Primary regulatory records, compound data, clinical trials and peer-reviewed sources for Daraxonrasib, Vopimetostat, Zoldonrasib and Silevertinib.

Editorial standard

Trace every important statement back to a source.

Medical and regulatory information changes. We prioritize FDA, NCBI, ClinicalTrials.gov and original peer-reviewed publications, show review dates on medical explainers and separate Daraxon product statements from independently published evidence.

Development programs

PubChem · Daraxonrasib

Daraxonrasib API / RMC-6236

Research context: RAS(ON) multi-selective inhibitor.

Open primary source

Tango Therapeutics · Vopimetostat / PRMT5

Vopimetostat API / TNG462

Research context: PRMT5 / MTAP-deleted cancers.

Open primary source

Revolution Medicines · Zoldonrasib / RMC-9805

Zoldonrasib API / RMC-9805

Research context: RAS(ON) G12D-selective inhibitor.

Open primary source

Black Diamond Therapeutics · Silevertinib / BDTX-1535

Silevertinib API / BDTX-1535

Research context: EGFR-mutant NSCLC / EGFR-altered glioblastoma.

Open primary source

Regulatory

U.S. FDA · 26 August 2026

FDA approves daraxonrasib for metastatic pancreatic adenocarcinoma

Official approval notice identifying RASONQUE, its active ingredient, sponsor and approved population.

Open primary source

U.S. FDA · current list

2026 Novel Drug Approvals

FDA’s annual list records Rasonque (daraxonrasib) and the approval date.

Open primary source

U.S. FDA · 2026 Q3

List of Drug Master Files

FDA 2026 Q3 records: Daraxonrasib 43871, Vopimetostat 44318, Zoldonrasib 44304 and Silevertinib 44854. All four are Type II, status A, under SHANGHAI DA'AN XIN BIOMEDICAL CO LTD.

Open primary source